NERM
ALNY icon

New England Research & Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

New England Research & Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,100
Closed -$607K – 134
2020
Q2 		$607K Buy
+4,100
New +$553K 0.43% 81

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

New England Research & Management's ALNY Position: Q3 2020 in Review

New England Research & Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2020, closing a stake of 4,100 shares — an estimated $607K sold.

New England Research & Management first reported a position in ALNY in Q2 2020 and held it in 1 quarter. The position peaked at $607K in Q2 2020. 356 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

  • New England Research & Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • New England Research & Management sold 4,100 Alnylam Pharmaceuticals shares in Q3 2020, an estimated $607K.
  • New England Research & Management first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • New England Research & Management's Alnylam Pharmaceuticals position peaked at $607K in Q2 2020.
  • 356 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on New England Research & Management's 13F filing for Q3 2020, filed 8 Oct 2020.